Report
Pharvaris Supportive data at C1-Inhibitor Deficiency and Angioedema Workshop
Pharvaris provided a summary of data that was presented at the C1-Inhibitor Deficiency and Angioedema Workshop, held 29 May – 1 June. The presentations continue to be supportive of deucrictibant's differentiated profile in HAE and included i) data that supports dual use of B2 antagonism for LTP and ODT in the same patients, ii) limited symptom recurrence showing durability of on-demand treatment, as well as iii) a novel biomarker assay that could help identify BK mediated angioedema. We reiterate our $32 TP and Buy rating.
Underlying
Pharvaris NV
Provider
KBC Securities
We are a financial services provider for several types of professional clients, each with distinct needs.
Jacob Mekhael
Other Reports on these Companies
Other Reports from KBC Securities
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.